StockDriftsStockDriftsTop 9 Foresite Capital Opportunity Management V, Llc Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PRDS | Pardes Biosciences Inc | 29.04% | 5.23M | $10K | new | — | 2022-09-30 | |
| THRX | Theseus Pharmaceuticals, Inc. | 16.71% | 959.3K | $6K | new | — | 2022-09-30 | |
| GMTX | Gemini Therapeutics, Inc. | 11.99% | 2.44M | $4K | new | — | 2022-09-30 | |
| CMPX | Compass Therapeutics, Inc. | 10.64% | 1.55M | $4K | new | — | 2022-09-30 | |
| KNTE | Kinnate Biopharma Inc. | 10.46% | 291.7K | $3K | new | — | 2022-09-30 | |
| ACET | Adicet Bio, Inc. | 7.26% | 170.0K | $2K | new | — | 2022-09-30 | |
| QSI | Quantum-Si Incorporated | 5.23% | 633.6K | $2K | new | — | 2022-09-30 | |
| HIMS | Hims & Hers Health, Inc. | 5.13% | 306.4K | $2K | new | — | 2022-09-30 | |
| ENTA | Enanta Pharmaceuticals, Inc. | 3.54% | 22.8K | $1K | new | — | 2022-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — |
| Top 20 Holdings Unweighted | — | — | — | — |
Foresite Capital Opportunity Management V, Llc reports $33.31K in US-listed equity holdings across 9 positions in its most recent 13F filing. Its largest disclosed positions are PRDS (29.0%), THRX (16.7%) and GMTX (12.0%). Figures reflect the Q3 2022 filing.
Sign up free to track Foresite Capital Opportunity Management V, Llc, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Foresite Capital Opportunity Management V, Llc’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1792207). View Foresite Capital Opportunity Management V, Llc’s 13F filings on SEC